TRK fusions are found in a variety of cancer types, lead to oncogenic addiction, and strongly predict tumor-agnostic efficacy of TRK inhibition [1] [2] [3] [4] [5] [6] [7] [8] . With the recent approval of the first selective TRK inhibitor, larotrectinib, for patients with any TRK-fusion-positive adult or pediatric solid tumor, to identify mechanisms of treatment failure after initial response has become of immediate therapeutic relevance. So far, the only known resistance mechanism is the acquisition of on-target TRK kinase domain mutations, which interfere with drug binding and can potentially be addressable through second-generation TRK inhibitors 9-11 . Here, we report off-target resistance in patients treated with TRK inhibitors and in patient-derived models, mediated by genomic alterations that converge to activate the mitogen-activated protein kinase (MAPK) pathway. MAPK pathway-directed targeted therapy, administered alone or in combination with TRK inhibition, re-established disease control. Experimental modeling further suggests that upfront dual inhibition of TRK and MEK may delay time to progression in cancer types prone to the genomic acquisition of MAPK pathway-activating alterations. Collectively, these data suggest that a subset of patients will develop off-target mechanisms of resistance to TRK inhibition with potential implications for clinical management and future clinical trial design.
TRK fusions are found in a variety of cancer types, lead to oncogenic addiction, and strongly predict tumor-agnostic efficacy of TRK inhibition [1] [2] [3] [4] [5] [6] [7] [8] . With the recent approval of the first selective TRK inhibitor, larotrectinib, for patients with any TRK-fusion-positive adult or pediatric solid tumor, to identify mechanisms of treatment failure after initial response has become of immediate therapeutic relevance. So far, the only known resistance mechanism is the acquisition of on-target TRK kinase domain mutations, which interfere with drug binding and can potentially be addressable through second-generation TRK inhibitors [9] [10] [11] . Here, we report off-target resistance in patients treated with TRK inhibitors and in patient-derived models, mediated by genomic alterations that converge to activate the mitogen-activated protein kinase (MAPK) pathway. MAPK pathway-directed targeted therapy, administered alone or in combination with TRK inhibition, re-established disease control. Experimental modeling further suggests that upfront dual inhibition of TRK and MEK may delay time to progression in cancer types prone to the genomic acquisition of MAPK pathway-activating alterations. Collectively, these data suggest that a subset of patients will develop off-target mechanisms of resistance to TRK inhibition with potential implications for clinical management and future clinical trial design.
To identify mechanisms of resistance to TRK inhibition in patients with TRK fusion-positive cancers, tumor biopsies and circulating cell-free DNA (cfDNA) were collected prospectively from patients treated with a variety of TRK inhibitors as part of prospective clinical trials and compassionate use programs. Paired sequencing was conducted (see Methods) to identify patients in whom TRK kinase domain mutations were not detected or did not entirely explain resistance to the TRK inhibitor used. Acquired alterations that involved upstream receptor tyrosine kinase or downstream MAPK pathway nodes were identified in six patients, prompting further analysis of these cases.
In the first patient (Patient 1), who had a CTRC-NTRK1 fusionpositive pancreatic cancer that developed resistance to larotrectinib, targeted sequencing of paired pre-treatment and post-progression tumor biopsies revealed an acquired BRAF V600E mutation ( . Consistent with the hypothesis that downstream MAPK pathway activation was responsible for TRK-independent bypass resistance, the disease progressed rapidly on subsequent treatment with LOXO-195, a second-generation TRK inhibitor designed to maintain potency in the setting of TRK kinase domain mutations 9 . In addition, the ectopic expression of BRAF V600E in a NTRK1 fusion-positive pancreatic cancer cell line (TPR-NTRK1, NTRK1 G595R ) conferred resistance to (Fig. 1c) , which further supports the idea that this alteration has a causative role in mediating resistance.
In the second patient (Patient 2), who had a LMNA-NTRK1 fusion-positive colorectal cancer (CRC) that developed acquired resistance to , sequencing of tumor and serial cfDNA samples revealed emergence of multiple KRAS mutations consistent with polyclonal resistance mediated by a convergent mechanism ( Fig. 1d and Extended Data Fig. 1d ,e). This patient previously had a prolonged response to larotrectinib followed by resistance driven by acquisition of an NTRK1 G595R solvent-front mutation (the resultant substitution prevents drug binding 11 ). Consistent with on-target NTRK-dependent resistance, subsequent treatment with LOXO-195 achieved a second response, eventually followed again by solitary site progression in the liver. Genomic analysis of the liver metastasis biopsy and serial cfDNA revealed the emergence of a KRAS G12A substitution ( Fig. 1d and Extended Data Fig. 1d,e) . This mutation disappeared in cfDNA after ablation of the liver metastasis Letters Nature MediciNe and LOXO-195 continuation; however, a new KRAS G12D mutation emerged upon further disease progression (Fig. 1d) Fig. 1f,g ). In further support of the causative nature of these alterations in mediating resistance, ectopic expression of both KRAS G12A and KRAS G12D in TRK fusion-positive CRC cell lines was sufficient to increase MAPK pathway activation and confer resistance to both larotrectinib and (Fig. 1e,f) .
In the third patient (Patient 3), who had a PLEKHA6-NTRK1 fusion-positive cholangiocarcinoma that developed acquired resistance to the first-generation TRK inhibitor entrectinib, sequencing of both tissue and cfDNA identified an acquired high-level , treated as indicated. Data are presented as mean ± s.d. Two-tailed unpaired t-test was used to evaluate significant differences in percentage of viable cells. Asterisk indicates differences that were considered statistically significant (P < 0.05). Exact P values are P = 0.000000000000001 for the LMNA-NTRK1 cell line and P = 0.000000001115265 for the LMNA-NTRK1, NTRK1 G595R cell line. Two biological replicates were performed for each experiment. g, Schematic showing acquired MET amplification in a patient with PLEKHA6-NTRK1 fusion-positive cholangiocarcinoma with acquired resistance to entrectinib. h,i, Representative FISH (h) and immunohistochemistry (IHC) (i) images of the pre-and post-entrectinib tumor biopsies from this patient. Lower panels show confirmed acquisition of MET amplification in the post-entrectinib sample (h) and increased MET and pERK staining by IHC (i). FISH and IHC were performed twice independently and similar results were obtained.
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focal amplification of MET (Fig. 1g) . Acquisition of MET highlevel amplification and protein overexpression was orthogonally confirmed by MET fluorescence in situ hybridization (FISH) and immunohistochemistry, respectively (Fig. 1h,i) , and sequencing of NTRK1 did not identify a kinase domain point mutation. Of note, MET amplification has been observed as a mechanism of off-target resistance in other oncogene-addicted cancers [12] [13] [14] [15] [16] . Consistent with the hypothesis that MET amplification drove TRK-independent resistance, the disease progressed immediately despite subsequent treatment with .
As all three index cases involved tumors of gastrointestinal origin, we next broadened our analysis to all patients with TRK fusionpositive gastrointestinal cancer for whom we had serial cfDNA samples (excluding gastrointestinal stromal tumors). Five additional patients were identified, three of whom developed emergent MAPK alterations while on TRK inhibitors (Supplementary Table 1 ). One patient with an ETV6-NTRK3 fusion-positive pancreatic cancer had a prolonged response to the multikinase TRK inhibitor PLX7486. No mechanism of resistance was identified at progression and he was subsequently treated with LOXO-195 with no response. At the time of progression on LOXO-195, cfDNA demonstrated acquisition of a hotspot MEK1 (MAP2K1) P124S mutation. Although testing within the context of a TRK fusion suggests that this mutation has weak oncogenic potential, this alteration has previously been proposed to confer resistance to targeted therapy in patients with BRAF V600E melanoma 17 . A second patient with TPR-NTRK1 fusion-positive pancreatic cancer had a prolonged response to entrectinib followed by resistance driven by acquisition of NTRK1 G595R . This patient was subsequently treated with LOXO-195 with a transient decline in tumor markers and resolution of tumor fevers, followed quickly by clinical deterioration and radiological progression. Serial cfDNA sequencing on LOXO-195 revealed loss of the NTRK1 G595R mutation but emergence of the known activating ERBB2 S310F mutation 18 . Lastly, a TPM3-NTRK1 fusion-positive CRC patient developed polyclonal resistance to larotrectinib 6 months into therapy, with cfDNA demonstrating emergence of KRAS
G12D
, NTRK1 G595R , and NTRK1 F589L at the time of clinical progression (Supplementary Table 1) .
Collectively, our analyses identified putative bypass-mediated resistance to first-and next-generation TRK inhibitors in 75% of (6 out of 8) TRK-fusion positive gastrointestinal cancers analyzed. These alterations are all predicted to restore MAPK signaling through parallel activation of upstream receptor tyrosine kinase and downstream MAPK signaling nodes. We therefore reasoned that these alterations represent a recurrent and convergent mechanism of treatment failure of TRK inhibitors and that a subset of these alterations may be pharmacologically actionable. ) n = 7). Combination therapy prevents the development of primary or acquired resistance (ongoing at 3 months). Two-tailed unpaired t-test was used to evaluate significant differences in the tumor volumes. Data are presented as mean ± s.e.m. P values < 0.05 were considered statistically significant.
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Simultaneously, a subclonal but preexisting KRAS G12D mutation arose in cfDNA, followed by radiographical progression shortly thereafter, which suggests that outgrowth of this alteration may have been responsible for the acquired resistance to RAF and MEK inhibition (Fig. 2a) . However, it is likely that this tumor was still partially driven by the TRK fusion. Although a combination including a TRK inhibitor as a third agent was favored initially, it could not be secured in time. We therefore tested whether the addition of a TRK inhibitor to the combination of dabrafenib and trametinib would enhance anti-tumor activity in TRK fusion-positive preclinical models transduced with sequences encoding BRAF V600E . Triple therapy (larotrectinib, dabrafenib, and trametinib) was significantly more effective than dabrafenib and trametinib at suppressing tumor growth and deeply inhibiting TRK-mediated signaling (AKT, ERK, MEK; Extended Data Fig. 3a,b) . Triple therapy also enhanced tumor growth inhibition compared to dabrafenib and trametinib in PDXs derived from Patient 1 that harbor the BRAF V600E mutation (Extended Data Fig. 3c ).
Patient 3, who had cholangiocarcinoma and the emergent MET amplification, was treated with the combination of LOXO-195, an agent on which her disease had just progressed, and the multikinase MET inhibitor, crizotinib. Marked tumor shrinkage was achieved at 8 weeks and disease control was maintained for 4.5 months, accompanied by the disappearance of detectable NTRK fusion and MET amplification in cfDNA ( Fig. 2b and Extended Data Fig. 4a,b) . Interestingly, post-progression cfDNA demonstrated reappearance of focal MET amplification in addition to 13 emergent missense mutations in MET (Fig. 2b and Extended Data Fig. 4b ), several of which are known to impair crizotinib binding 19, 20 . Although multiple resistance mechanisms were observed, presumably secondary to intertumoral or intratumoral heterogeneity, these alterations were remarkably convergent on MET reactivation. This on-target resistance to crizotinib further supports the mechanistic role for MET as an acquired driver of resistance to prior TRK inhibitor therapy.
Although the tumor regressions observed in patients with acquired BRAF V600E and MET amplifications were ultimately transient, they provide further clinical validation that the putative bypass mechanisms identified in these patients were biologically relevant. Given the convergence of these alterations on MAPK pathway activation, we explored the utility of combination TRK and MEK inhibition preclinically and clinically. Combinatorial treatment with LOXO-195 and a MEK inhibitor (trametinib or MEK-162) was more effective than either single agent alone in suppressing TRK and ERK activation and cell viability in the LMNA-NTRK1, NTRK1 G595R , KRAS G12D LOXO-195-resistant model (Fig.  3a,b and Extended Data Fig. 5a,b) . Furthermore, xenografts derived from this cell line were more sensitive to combinatorial therapy compared to each of the single agents (Fig. 3c) , and similar results were obtained from PDXs established from the LOXO-195-resistant tumor collected from Patient 2 (KRAS
G12A
, LMNA-NTRK1-positive CRC; Fig. 3d ). Despite these observations, Patient 2 was treated with the combination of LOXO-195 and trametinib and experienced rapid disease progression (Extended Data Fig. 6 ). Although the KRAS mutations in the patient and the PDX had different G12 substitutions (a factor that can affect GTPase activity and consequent response to MEK inhibition 21 ), this outcome was also consistent with prior clinical experience showing that KRAS mutations are insensitive to MEK inhibition at exposures achievable in people 22, 23 . However, in multiple oncogene-addicted cancers, the management of acquired resistance with next-generation inhibitors or combinatorial therapy has generally been less efficacious than upfront use of these agents [24] [25] [26] . We therefore reasoned that the upfront dual targeting of TRK and MEK might delay the emergence of off-target resistance that converges on downstream MAPK pathway activation in TRK fusion-positive models. To test this hypothesis, we treated the larotrectinib-resistant and sensitive PDXs established from Patient 1 with larotrectinib, trametinib, or a combination of both. In larotrectinib-resistant PDXs, the combination of larotrectinib and trametinib delayed but did not prevent tumor growth compared to single agent treatments (Fig. 3e) . In larotrectinib-sensitive PDXs, single-agent larotrectinib effectively controlled tumor growth for approximately 1 month, but the combination resulted in complete and durable tumor regression (ongoing response at 3 months; Fig. 3f ). Droplet digital PCR on residual responding tumors collected at the end of the experiment from mice treated with the combination found that the BRAF V600E mutation was indeed present, albeit at low variant allele frequency (Supplementary Table 2 ), suggesting that concomitant TRK and MEK inhibition limited the emergence of this resistant cell population. If recapitulated in additional models, these data suggest that the upfront combination may further delay the emergence of MEK-sensitive resistance mechanisms such as the BRAF V600E mutation, compared to sequential TRK inhibitor monotherapy followed by the combination upon development of clinical resistance 27 . Together, our data suggest that a subset of TRK fusion-positive cancers will develop off-target resistance to TRK inhibition that will not be adequately addressed by next-generation TRK inhibitors alone. Intriguingly, although TRK fusions seem to predict an initial response to TRK inhibition in a tumor-agnostic manner, early clinical evidence suggests that the durability of response may be more limited in gastrointestinal cancer 2, 11, 28 . Our findings provide potential mechanistic insight into why this may be the case and show similarities to prior experience with targeted therapy in BRAF V600E or EGFR-amplified CRCs [29] [30] [31] [32] . The bypass mechanisms we identified demonstrate remarkable convergence on the ERK signaling. A portion of these resistance mechanisms may be managed successfully with simultaneous TRK and MEK inhibition, drugs that have largely non-overlapping toxicity in patients, although upfront treatment with the combination may confer more durable responses.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of code and data availability and associated accession codes are available at https://doi.org/10.1038/ s41591-019-0542-z.
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Methods
Ethical compliance. We declare compliance with all relevant ethical regulations.
Patients. Patients were treated with TRK inhibitors as part of prospective IRBapproved research protocols or expanded access protocols. All patients provided written informed consent for genomic sequencing of tumor and cfDNA, and review of medical records for detailed demographic, pathological, and clinical data, and for publication of this information as part of an institutional IRBapproved research protocol (Memorial Sloan Kettering Cancer Center (MSKCC); NCT01775072). Research protocols for tumor collection and analysis were approved by the ethical committees of the MSKCC.
Compounds. Larotrectinib and LOXO-195 were obtained from Loxo Oncology. Trametinib and MEK-162 were purchased from Selleckchem. All drugs were dissolved in DMSO to yield 10 mM stocks and stored at −20 °C.
Targeted tumor sequencing. DNA from formalin-fixed paraffin-embedded tissue and matched germline DNA underwent targeted next-generation sequencing assay using MSK-IMPACT 33 . In brief, this assay uses a hybridization-based exon capture designed to capture all protein-coding exons and select introns of oncogenes, tumor-suppressor genes, and key members of pathways that may be actionable by targeted therapies. In this study, either 410 or 468 key cancer-associated genes were analyzed. Sequencing data were analyzed as described previously to identify somatic single-nucleotide variants, small insertions and deletions, copy number alterations, and structural rearrangements 34 . In addition, hotspot alterations were identified using an adaptation of a method described previously 35 applied to a cohort of 24,592 sequenced human cancers 36 .
Targeted plasma sequencing. Cell-free DNA was extracted from all plasma samples and sequenced using a custom, ultra-deep coverage next-generation sequencing panel (MSK-ACCESS). The custom assay includes key exons and domains of 129 genes and introns of 10 genes harboring recurrent breakpoints, and uses duplex unique molecular identifiers (UMIs) and dual index barcodes to minimize background sequencing errors and sample-to-sample contamination. Sequencing data were analyzed using a custom bioinformatics pipeline that trims the UMIs, aligns the processed reads to the human genome, collapses PCR replicates into consensus sequences, and re-aligns the error-suppressed consensus reads. Consensus reads with representation from both strands of the original cfDNA duplex were used for de novo variant calling using VarDict (v1.5.1). Mutation calling required at least one collapsed read at a known cancer hotspot site or at least three collapsed reads at non-hotspot sites. All samples were sequenced to an average depth of approximately 20,000× coverage. Somatic mutations were identified and quantified as variant allele frequencies. Copy number alterations were identified across all samples using a method described previously 34 . NTRK fusions were identified and quantified using Manta (v1.5.0). All samples were reviewed manually to identify NTRK fusions, and cfDNA from Patient 3 was reviewed manually to identify copy number alterations, including MET. Variants were called against an unmatched healthy plasma donor to identify any specimen type-related artifacts. Mutations called at silent, intronic, and intergenic loci were removed. Immunohistochemistry. C-Met immunohistochemistry was performed with clone SP44 (Ventana Medical Systems) at a concentration of 9.75 µg ml −1 and ready to use dilution. Trk A immunohistochemistry was performed with clone EP105BY (Abcam) at a concentration of 0.643 mg ml −1 and 1:750 dilution. Both C-Met and Trk A immunohistochemistry are clinically validated and were performed in a CLIA (Clinical Laboratory Improvement Amendments) accredited laboratory. pERK immunohistochemistry was performed with clone D13.14.4E (Cell Signaling Technology) at a concentration of 1 µg ml −1 by the Molecular Cytology Core Facility at the MSKCC using Discovery XT processor (Ventana Medical Systems).
Patient
Fluorescence in situ hybridization. MET FISH was performed using the ZytoLight SPEC dual-color MET/CEN17 probe cocktail (Zytovision). MET FISH is a clinically validated assay that was performed in a CLIA accredited laboratory.
Plasmids and viral-particle production. pDONR223_KRAS_p.G12A (cat. 81673) was purchased from Addgene. The pDONR223_KRAS_wt and p.G12D were generated by site-directed mutagenesis using the Q5 Site-Directed Mutagenesis Kit (E0552S New England Biolabs) and primers pDNRmutG12Atowt F GTTGGAGCTGGTGGCGTAGGC, pDNRmutG12AtoD F GTTGGAGCTGATGGCGTAGGC and the common reverse pDNRmut R TACCACAAGTTTATATTCAGTCATGGTGC. The pDONR plasmids were then subcloned in the pLX302 destination lentiviral vector (Addgene, cat. 25896). Lentiviral particles were produced in HEK 293 T cells as described previously 37 , and used to infect the LMNA-NTRK1 and the LMNA-NTRK1, NTRK1 G595R cell lines. pLENTI6 lentiviral plasmids encoding for wild type and BRAF
V600E
were obtained from N. Rosen's laboratory and used to infect the TPR-NTRK1, NTRK1 G595R cell line. Transduced cell lines were used for western blot analyses and proliferation assays.
Proliferation assays. For cell-titer glo-based assays, LMNA-NTRK1 and LMNA-NTRK1, NTRK1
G595R cell lines transduced with KRAS wild-type or mutant-encoding plasmids were seeded in 96-well plates (6,000 per well). The following day larotrectinib or LOXO-195 (1:2 dilutions starting with a maximum concentration of 100 nM) was added. Cell-titer glo reagent was added 72 h later and absorbance was read at 490 nm according to the manufacturer's protocol. Data are presented as per cent cell viability (mean ± s.d.) normalized to the DMSO treated cells considered 100% viable. Cell-titer glo was also used to test the viability of LMNA-NTRK1, NTRK1
G595R and LMNA-NTRK1, NTRK1 G595R , KRAS G12D cell lines following treatment with LOXO-195 (125 nM) or the combination of LOXO-195 (125 nM) and trametinib (2 nM). For the colony formation assay, a TPR-NTRK1, NTRK1 G595R pancreatic cancer cell line transduced with sequences encoding wildtype BRAF or BRAF V600E was seeded in 6-well plates (300,000 cells per well). The following day, 50 nM of LOXO-195 were added. After 72 h of incubation cells were fixed in 4% glutaraldehyde and stained with crystal violet.
In vivo studies. Xenografts derived from the LMNA-NTRK1, NTRK1 G595R , KRAS G12D CRC primary cell line were generated by injecting 5 million cells into the flank of 6-week-old NSG female mice. Two weeks later, tumors were collected and expanded in additional mice. PDXs were generated as follows: 6-weekold NSG female mice were implanted subcutaneously with specimens freshly collected from patients at the Memorial Sloan Kettering (MSK) Hospital under an MSK approved IRB biospecimen protocol. Tumors developed within 2 to 4 months and were expanded into additional mice by serial transplantation. The generated PDXs were subjected to high-coverage next-generation sequencing with the MSK-IMPACT assay. For efficacy studies, treatment started when tumors reached approximately 100 mm Mice were observed daily throughout the treatment period for signs of toxicity. Tumors were measured twice weekly using calipers, and tumor volume was calculated using the formula, length × width 2 × 0.52. Body weight was also assessed twice weekly. At the end of each treatment, animals were euthanized and tumors were collected for biochemistry and histology analysis. Mice were cared for in accordance with guidelines approved by the MSK Institutional Animal Care and Use Committee and Research Animal Resource Center. Four to eight mice per group were included in each experiment.
Statistical analysis. Statistical analysis was conducted using GraphPad Prism 8 (GraphPad Software). Two-tailed unpaired t-tests were used to evaluate significant differences in the percentage of viable cells in cell proliferation assays. Data are presented as means ± s.d. Exact P values are indicated. Two-tailed unpaired t-tests were also used to evaluate significant differences in the tumor volumes in in vivo efficacy studies. Error bars represent s.e.m. Exact P values are indicated.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
All genomic results and associated clinical data for all patients in this study are publically available in the cBioPortal for Cancer Genomics at http://cbioportal.org/ The triple therapy is more potent than the combination of anti RAF/MEK alone in inhibiting MEK, ERK and AKT. Two biological replicates were performed. c, Efficacy of the triple therapy (larotrectinib + debrafenib + trametinib) against the Patient 1-derived PDX that harbors a V600E mutation. The triple therapy is significantly more efficacious than the combination of dabrafenib and trametinib alone in inhibiting tumor growth (P = 0.000001). A minimum of six animals per group [vehicle (n = 7), larotrectinib (n = 6), dabrafenib + trametinib (n = 7) and larotrectinib + dabrafenib + trametinib (n = 6)] were used. Two-tailed unpaired t-test was used to evaluate significant differences in the tumor volumes. Data are presented as mean±SEM. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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Data collection
An institutional IRB-approved research protocol (MSKCC; NCT01775072) was used for the collection of patients' information. No software was used to collect the data.
Data analysis
MSK-IMPACT was used as targeted next-generation sequencing platform. The MSK-IMPACT data analysis pipeline can be found here: https://github.com/rhshah/IMPACT-Pipeline. MSK-ACCESS was used as ultra-deep coverage next-generation sequencing panel for cfDNA analysis. VarDict (v1.5.1) was used for de novo variant calling and Manta (v1.5.0) for fusion calling. GraphPad Prism v. 8 was used for data analysis and statistical tests.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability a data availability statement has been added to the manuscript on pages 11-12. All genomic results and associated clinical data for all patients in this study are publically available in the cBioPortal for Cancer Genomics at the following URL: http://cbioportal.org/msk-impact.
nature research | reporting summary
October 2018
Field-specific reporting Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection. All studies must disclose on these points even when the disclosure is negative.
Sample size
No statistical methods were used to predetermine sample size. Sample size was based on experimental feasibilty, sample availability, and N necessary to obtain definitive results.
Data exclusions none Replication
All experimental findings were reproduced at least twice, with the exception of the in vivo experiments in which, however, a minimum of 5 animals per arm was utilized. Animals' randomization was performed for all the in vivo studies just before starting the treatments to assign animals to the different arms. Tumor volume average at this time point was set at 100 mm3. Unpaired T-Test was performed to ensure that differences in tumor volume in the different groups were not significant.
Randomization Randomization was not part of the design of the larotrectinib clinical trials (NCT02122913, NCT02637687 and NCT02576431) or the entrectinib clinical trials (EudraCT 2012-000148-88 and NCT02097810) or the LOXO-195 trial (NCT03215511) considered in this study. Randomization is not relevant to the current studies as the object was to decipher the mechanisms of sensitivity to targeted therapies within individual patients.
Blinding
Patients and clinicians were not blinded for the clinical trials referenced in this paper. Specifically, blinding was not part of the design of the larotrectinib clinical trials (NCT02122913, NCT02637687 and NCT02576431), the entrectinib clinical trials (EudraCT 2012-000148-88 and NCT02097810), or the LOXO-195 trial (NCT03215511). These studies did not involve randomization and all patients enrolled were treated with the investigational agents.
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. 
